- Home
- RDCM vs MSLE Comparison
RDCM vs MSLE Comparison
Compare RDCM & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDCM | MSLE |
|---|---|---|
| Founded | 1985 | N/A |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.6M | 154.6M |
| IPO Year | 1999 | 2007 |
Fundamental Metrics
Financial Performance| Metric | RDCM | MSLE |
|---|---|---|
| Price | $9.87 | $9.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | ★ 134.4K | 17.5K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.50 | N/A |
| Revenue Next Year | $9.74 | N/A |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.40 | $5.44 |
| 52 Week High | $16.74 | $13.39 |
Technical Indicators
Market Signals| Indicator | RDCM | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 33.20 | 46.77 |
| Support Level | $9.40 | $8.88 |
| Resistance Level | $10.79 | $9.75 |
| Average True Range (ATR) | 0.26 | 0.50 |
| MACD | 0.08 | -0.11 |
| Stochastic Oscillator | 20.86 | 23.40 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.